PRIDE-HD

Why is this study being done?
Huntington disease is associated with three types of symptoms: motor, behavioral, and cognitive. Dopamine is a chemical that is important for several aspects of brain function including motor. Currently there is not a drug that manages all the different types of motor symptoms. This study is to test a new drug to see:
• If it is helpful to people with HD

What is the drug being studied?
Pridopidine (TV-7820, formerly known as ACR16) is from a group of drugs which are believed to stabilize dopamine. There is evidence that the functioning of dopamine in the brain is a problem in HD.

How can you help?
If you have been diagnosed with HD, ask to speak to a member of the research team. We can explain the study, including benefits and risks. We will also talk to you to determine if the study is a good fit for you.

What is required if you participate?
• You and your caregiver will be asked to sign a consent form
• You and your caregiver will be required to participate in 10 in-person visits to complete
  o a physical examination
  o surveys/questionnaires
  o thinking tests
• You will have to provide blood and urine samples
• Take the study medication (or a placebo) as prescribed for 26 weeks.

Want more information or want to participate?
More information can be found at clinicaltrials.gov. You can also ask to speak to a member of the research team or contact

Ginger Norris, MGC, CGC
Research Manager
Phone: (804) 662-5307
email: vwnorris@vcu.edu

Claudia Testa, MD, PhD
Neurologist/Principal Investigator
Phone: (804) 662-5300
email: ctesta@vcu.edu